^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCL4-L

    i
    Other names: CCL4, Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4, Chemokine (C-C motif) ligand 4
    Entrez ID:
    6351
    Related biomarkers:
    Others
    1year
    THERAPEUTIC EFFECTS OF OGB21502, A NOVEL TETRA-SPECIFIC DRUG, IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) MICE MODELS (AASLD 2023)
    In the remaining 8 weeks, the mice were administered either OGB21502 or reference drugs (Fc-FGF21, obeticholic acid and semaglutide). Overall, a novel tetra-specific drug, OGB21502 improved glucose level, insulin resistance, liver damage, inflammation as well as liver fibrosis through multiple animal models. These results demonstrate the potential of OGB21502 as an important alternative for treating severe NASH with metabolic dysfunction and fibrosis, due to synergistic effects across multiple targets.
    Preclinical
    |
    TGFB1 (Transforming Growth Factor Beta 1) • FGF21 (Fibroblast Growth Factor 21) • IL1R1 (Interleukin 1 receptor, type I) • GCG (Glucagon)
    |
    CCL4-L